459 related articles for article (PubMed ID: 24251651)
1. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
2. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
[No Abstract] [Full Text] [Related]
3. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
4. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis in children with hemophilia: is it the optimal treatment?
Lusher JM
Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
[No Abstract] [Full Text] [Related]
6. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
7. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
8. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
9. Changing paradigm of prophylaxis with longer acting factor concentrates.
Carcao M
Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
[TBL] [Abstract][Full Text] [Related]
10. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
[TBL] [Abstract][Full Text] [Related]
11. Experience with prophylaxis in Sweden.
Nilsson IM
Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
[No Abstract] [Full Text] [Related]
12. Central venous access catheters in children with haemophilia.
Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
[TBL] [Abstract][Full Text] [Related]
13. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
Petrini P
Haemophilia; 2001 Jan; 7(1):99-102. PubMed ID: 11136389
[TBL] [Abstract][Full Text] [Related]
14. How to manage invasive procedures in children with haemophilia.
Ljung RC; Knobe K
Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
[TBL] [Abstract][Full Text] [Related]
15. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.
Ljung R; Aronis-Vournas S; Kurnik-Auberger K; van den Berg M; Chambost H; Claeyssens S; van Geet C; Glomstein A; Hann I; Hill F; Kobelt R; Kreuz W; Mancuso G; Muntean W; Petrini P; Rosado L; Scheibel E; Siimes M; Smith O; Tusell J
Haemophilia; 2000 Nov; 6(6):619-24. PubMed ID: 11122385
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
[TBL] [Abstract][Full Text] [Related]
17. Haemophilia treatment in the United Kingdom from 1969 to 1974.
Biggs R
Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Wang C; Young G
Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
[TBL] [Abstract][Full Text] [Related]
19. Attitudes and practices with regard to circumcision in haemophilia patients in Southern Iran.
Haghpanah S; Ardeshiri R; Zahedi Z; Golzadeh MH; Silavizadeh S; Karimi M
Haemophilia; 2013 May; 19(3):e177-8. PubMed ID: 23490218
[No Abstract] [Full Text] [Related]
20. Hemophilia and prophylaxis.
Ljung R
Pediatr Blood Cancer; 2013; 60 Suppl 1():S23-6. PubMed ID: 23109472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
